205 related articles for article (PubMed ID: 1305671)
1. Development of chemopreventive agents for bladder cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16I():1-12. PubMed ID: 1305671
[TBL] [Abstract][Full Text] [Related]
2. Introductory remarks: development of chemopreventive agents for prostate cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16H():1-8. PubMed ID: 1289663
[TBL] [Abstract][Full Text] [Related]
3. Development of chemopreventive agents for lung and upper aerodigestive tract cancers.
Kelloff GJ; Boone CW; Steele VK; Perloff M; Crowell J; Doody LA
J Cell Biochem Suppl; 1993; 17F():2-17. PubMed ID: 8412195
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of superficial bladder cancer.
Lieberman R
Cancer Treat Res; 2001; 106():237-54. PubMed ID: 11225005
[TBL] [Abstract][Full Text] [Related]
5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
6. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
7. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of bladder cancer.
Kamat AM; Lamm DL
Urol Clin North Am; 2002 Feb; 29(1):157-68. PubMed ID: 12109342
[TBL] [Abstract][Full Text] [Related]
11. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
12. Retinoids in the chemoprevention of bladder cancer.
Sabichi AL; Lerner SP; Grossman HB; Lippman SM
Curr Opin Oncol; 1998 Sep; 10(5):479-84. PubMed ID: 9800121
[TBL] [Abstract][Full Text] [Related]
13. Expectant management of small, recurrent, noninvasive papillary bladder tumors.
Soloway MS; Bruck DS; Kim SS
J Urol; 2003 Aug; 170(2 Pt 1):438-41. PubMed ID: 12853794
[TBL] [Abstract][Full Text] [Related]
14. Intermediate endpoint biomarkers for chemoprevention.
Hemstreet GP; Rao JY; Hurst RE; Bonner RB; Jones PL; Vaidya AM; Fradet Y; Moon RC; Kelloff GJ
J Cell Biochem Suppl; 1992; 16I():93-110. PubMed ID: 1305696
[TBL] [Abstract][Full Text] [Related]
15. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group.
Kurth KH; Bouffioux C; Sylvester R; van der Meijden AP; Oosterlinck W; Brausi M
Eur Urol; 2000; 37 Suppl 3():1-9. PubMed ID: 10828681
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
17. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of superficial bladder cancer.
Gee J; Sabichi AL; Grossman HB
Crit Rev Oncol Hematol; 2002 Sep; 43(3):277-86. PubMed ID: 12270783
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of superficial bladder cancer.
Kamat AM
Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
[TBL] [Abstract][Full Text] [Related]
20. Strategies of chemoprevention based on antigenic and molecular markers of early and premalignant lesions of the bladder.
Fradet Y; Lafleur L; LaRue H
J Cell Biochem Suppl; 1992; 16I():85-92. PubMed ID: 1305695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
